1. Search Result
Search Result
Results for "

HLA-A2

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

14

Peptides

1

Inhibitory Antibodies

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P10493

    Amino Acid Derivatives Cancer
    NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy [2].
    NY-ESO-1 (157-165) peptide
  • HY-P10493A

    Amino Acid Derivatives Cancer
    NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy [2].
    NY-ESO-1 (157-165) peptide TFA
  • HY-P1778A

    HPV Infection
    HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas [2].
    HPV16 E7 (86-93) (TFA)
  • HY-P4032

    HCV Inflammation/Immunology
    HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .
    HCV Peptide (35-44)
  • HY-P991247

    MHC Cancer
    Anti-HLA-A2 (Hu8F4) is a human monoclonal antibody (mAb) targeting HLA-A2. Anti-HLA-A2 (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Anti-HLA-A2 (Hu8F4)
  • HY-P1700

    TNF Receptor Cancer
    BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors .
    BCMA72-80
  • HY-P1881

    HPV Cancer
    HPV16-E711-20 epitope is a well-known HLA-A *0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .
    HPV16-E711-20 epitope
  • HY-P1778

    HPV Infection
    HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas [2].
    HPV16 E7 (86-93)
  • HY-RS06208

    DQB2; HLA-DXB; HLA-DQB1

    Small Interfering RNA (siRNA) Others

    HLA-DQB2 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQB2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HLA-DQB2 Human Pre-designed siRNA Set A
    HLA-DQB2 Human Pre-designed siRNA Set A
  • HY-RS06206

    DQA1; HLA-DCA; HLA-DXA; HLADQA2; DC-alpha; DX-ALPHA

    Small Interfering RNA (siRNA) Others

    HLA-DQA2 Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-DQA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    HLA-DQA2 Human Pre-designed siRNA Set A
    HLA-DQA2 Human Pre-designed siRNA Set A
  • HY-P5294

    EBV Cancer
    YLLEMLWRL is an HLA-A2-restricted T cell epitope sequence corresponding to codon 125-133. Among them, YLLEMLWRL sequence is the main mutation site of HLA-A2-restricted CTL epitope sequence .
    YLLEMLWRL
  • HY-P1919

    Tyrosinase Cancer
    Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy [2].
    [Asp371]-Tyrosinase (369-377), human
  • HY-P1855

    EGFR Cancer
    HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers [2].
    HER2/neu (654-662) GP2
  • HY-P3248

    Myelin basic protein (85-99) antagonist

    Biochemical Assay Reagents Inflammation/Immunology
    J5 peptide is an MBP inhibitor that competitively inhibits the binding of MBP85-99 to HLA-DR2. J5 peptide alleviates PLP139-151/MBP85-99-induced experimental autoimmune encephalomyelitis (EAE) in mice. J5 peptide can be used in research on inflammatory and immune diseases .
    J5 peptide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: